Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–3 of 3 results
Advanced filters: Author: Maxime Culot Clear advanced filters

  • GLP-1–GIP–lanifibranor, a single-molecule agonist of GLP-1R, GIPR, PPARα, PPARγ and PPARδ, shows promising therapeutic efficacy against obesity-linked metabolic dysfunction in vitro and in mouse models via synergistic incretin and PPAR activity.

    • Daniela Liskiewicz
    • Aaron Novikoff
    • Timo D. Müller
    ResearchOpen Access
    Nature
    P: 1-10

  • Inhibiting insulin-degrading enzyme (IDE) has been proposed as a potential therapeutic strategy for the treatment of patients with diabetes. Here, the authors develop a novel IDE inhibitor but find that, surprisingly, IDE inhibition has negative effects on glucose tolerance in mice.

    • Rebecca Deprez-Poulain
    • Nathalie Hennuyer
    • Benoit Deprez
    ResearchOpen Access
    Nature Communications
    Volume: 6, P: 1-13

  • In vitromodels of the blood–brain barrier (BBB) allow predictions of brain uptake for candidate drugs. Providing guidance through the plethora of BBB models, the authors discuss the pros and cons of different models, and their applications at various stages of drug discovery and development.

    • Romeo Cecchelli
    • Vincent Berezowski
    • Laurence Fenart
    Reviews
    Nature Reviews Drug Discovery
    Volume: 6, P: 650-661